Cynomolgus IGFBP2 Protein (His Tag)

Insulin-like growth factor binding protein 2, 36kDa Protein Datasheet

IGFBP2 Protein Product Information

• Synonym: IGFBP2
• Protein Construction: A DNA sequence encoding the Cynomolgus IGFBP2 (F6YKM5) (Met1-Gln324) was expressed, fused with a polyhistidine tag at the C-terminus.
• Source: Cynomolgus
• Expression Host: Human Cells

IGFBP2 Protein QC Testing

• Purity: > 67 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu 38
• Molecular Mass: The recombinant Cynomolgus IGFBP2 is a disulfide-linked homodimer. The reduced monomer comprises 300 amino acids and has a calculated molecular mass of 32.8 KDa. The apparent molecular mass of Cynomolgus IGFBP2 heterodimer is approximately 37 KDa respectively in SDS-PAGE.
• Formulation: Lyophilized from sterile PBS, pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: IGFBP2 protein

IGFBP2 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

IGFBP2 Protein Description

IGFBP-2, also known as IGFBP2, is a insulin-like growth factor-binding protein (IGFBP). IGFBPs play an integral role in modifying insulin-like growth factor (IGF) actions in a wide variety of cell types. There are six members in this family. They are structurally related but encoded by distinct genes. IGFBPs have a high affinity for IGFs. Some members of the IGFBP family have been consistently shown to inhibit IGF actions by preventing them from gaining access to the IGF receptors, while others potentiate IGF actions by facilitating the ligand-receptor interaction. IGFBP-2 contains 1 IGFBP N-terminal domain and 1 thyroglobulin type-1 domain. It inhibits IGF-mediated growth and developmental rates. IGFBP-2 is overexpressed in many malignancies and is often correlated with an increasingly malignant status of the tumor, pointing to a potential involvement of IGFBP-2 in tumorigenesis.

References

1. Han VK. et al., 1996, J Clin Endocrinol Metab. 81 (7): 2680-93.
2. Binkert C. et al., 1989, EMBO J. 8 (9): 2497-502.
3. Wolf E. et al., 2000, Pediatr Nephrol. 14 (7): 572-8.